ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Representatives of EnteroMedics Inc. (the “Company”) intend to make presentations at investor conferences and in other forums and these presentations may include the information contained in Exhibit99.1 attached to this Current Report on Form8-K. A copy of thepresentationslides containing such information that may be disclosed by the Company is attached as Exhibit99.1 to this report and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The Company intends to disclose the information contained in Exhibit99.1, in whole or in part, and with updates and possibly modifications, in connection with presentations to investors, analysts and others during the remainder of 2017 or until an updated presentation is made available by the Company.

The Company is furnishing the information contained in Exhibit99.1 to Regulation FD and Item 7.01 of Form8-K promulgated by the Securities and Exchange Commission (“SEC”). This information shall not be deemed to be “filed” with the SEC for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

The information contained in Exhibit99.1 is summary information that is intended to be considered in the context of the Company’s SEC filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in Exhibit99.1, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. By filing this report and furnishing this information, the Company makes no admission as to the materiality of any information contained in this report, including Exhibit99.1.

Item 8.01 Other Events.

The Company is providing certain information as an update to and to supersede the information provide in the Company’s previous periodic filings with the SEC in order to reflect recent business developments. An updated description of the Company’s business and risk factors are attached hereto as Exhibit99.2 and 99.3, respectively, and are incorporated herein by reference. The information in this Item 8.01 (including Exhibits 99.2 and 99.3) should be read in conjunction with the Company’s Annual Report on Form10-K for the year ended December31, 2016, the Company’s Quarterly Report on Form10-Q for the quarter ended March31, 2017, and the Company’s Current Reports on Form8-K filed with the SEC since January1, 2017.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

Investor Presentation Slides

99.2

Updated Business Summary

99.3

Updated Risk Factors


EnteroMedics Inc Exhibit
EX-99.1 2 a17-18401_2ex99d1.htm EX-99.1 Exhibit 99.1   NASDAQ: ETRM Company Presentation 2017 Confidential information. Do not distribute.   2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as expect,…
To view the full exhibit click here

About ENTEROMEDICS INC. (NASDAQ:ETRM)

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.